Lupin gets US FDA approval for Ceftriaxone 10gm vials

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, 14 September 2006: Lupin Ltd., announced today that the US FDA has approved the Company's Abbreviated New Drug Application (ANDA) for its Ceftriaxone Injection 10 gram vials (Pharmacy bulk pack). Ceftriaxone is the generic equivalent of Rocephin® marketed by Roche.

Lupin had launched the 250 mg, 500 mg, 1 g and 2 g strengths of Ceftriaxone vials upon patent expiry in July, 2005.

"The approval of our Ceftriaxone 10mg ANDA completes the entire Ceftriaxone product family. Again our preparedness for execution enables us to launch this product immediately," said Dr. Kamal Sharma, Managing Director, Lupin.

The Company has agreements with Baxter Healthcare Corporation for the U.S. hospital market and with Henry Schein, Inc. for the physician offices.

With this approval, Lupin now has 15 ANDAs approved by the US FDA.

About Lupin
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the quarter year ended June 2007, the Company's Revenues and Profit after Tax were Rs.4,851 million (US$ 105 million) and Rs.507 million (US$ 11 million) respectively.

For further information contact:
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com